Global Orphan Cancer Drug Market, Drug Sales, Price & Clinical Trials Insight 2028

List of Tables

“Global Orphan Cancer Drug Market, Drug Sales, Price & Clinical Trials Insight 2028” Report Highlights:

Global Orphan Designated Market Opportunity > USD 170 Billion by 2028

Global & Regional Market Size 2022 Till 2028

Market Size By Orphan Designated Cancer Type 2022 Till 2028

Top 50 Orphan Designated Cancer Drug Sales Forecast Till 2028

Top 50 Drugs Account For > 70% Of Global Orphan Cancer Drug Market

Top 50 Drugs Pricing, Dosage, Patent Insight

Orphan Designated Cancer Drug Clinical Trials Insight by Company, Country & Indication

Insight On More Than 400 Orphan Designated Cancer Drugs in Clinical Trials

Insight On More Than 200 Orphan Designated Cancer Drugs Commercially Available in Market

Orphan cancer drugs are novel pharmaceuticals which are indicated for the prevention, diagnosis, or treatment of rare cancers. These rare cancers are chronic and life-threatening which requires proper long-term medications. As these diseases are rare, therefore the drug development of these diseases requires considerable amount of investment, thus increasing the overall cost of the drug. However, the passage of orphan drug development act in 1983 has opened avenues for the development of novel orphan drugs which are intended for the management of these cancers. The passage of this act incentivizes the pharmaceutical companies to actively invest in this segment. Till date, more than 700 drugs have been granted orphan designation for the management of orphan designated cancers.

This rapid increase in the designation also appears to have translated into an increase in approvals and commercialization of these drugs. As of now, more than 200 drugs have been commercially available for the management of rare cancers. Several biological drugs such as Herceptin, Rituximab, Blincyto, Kymriah, Opdivo, Keytruda, Yervoy, and others have been granted orphan designations which have shown encouraging response in the market owing to their targeted mechanism of action. The sales of these drugs have been tremendously increasing from past few years, which have encouraged the further research and development activities in this domain.

The global orphan cancer drug market is highly concentrated with several key layers including Mersana Therapeutics, Bristol Myers Squibb, Immunocore, Amgen, Genmab, Roche, Lava Therapeutics, and others. The key players are actively receiving orphan drug designation by the regulatory bodies which are expediting their clinical trials and approval process. For instance in 2022, Mersana Therapeutics has received orphan drug designation from US FDA to XMT-2056 for the management of gastric cancer. XMT-2056 is an investigational STING-agonist antibody drug conjugate (ADC) which is developed using the company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). The company has planned to initiate phase-I trial of XMT-2056 in a range of HER2 expressing tumors, such as breast, gastric and non-small-cell lung cancers, in mid 2022.

In last few years, pharmaceutical companies have begun to embrace a more collaborative way of working to mitigate the obstacles of drug development. For instance, Immunocore entered into clinical trial collaboration and supply agreement with Sanofi. Under the terms of agreement, Sanofi will evaluate it's precisely PEGylated, engineered version of IL-2, SAR444245, in combination with Kimmtrak, Immunocore's novel bispecific protein targeting gp100, in HLA-A*02:01 positive patients with advanced unresectable or metastatic skin cancers as part of Sanofi's ongoing Phase 1/2 study. The novel bispecific protein has been granted orphan drug designation by US FDA.

Despite several benefits associated with orphan cancer drug development, few factors restrain their growth in the market during the forecast period. Factors such as high cost of therapy, low prevalence of disease, difficulty in recruiting patients, lack of awareness among patients, and unavailability of diagnostic test for rare cancer hamper the growth of market. Although several challenges restrict the growth of market, but it is witnessed that the global orphan cancer drug market is continuously growing from past few years.

As per our report findings, the global orphan cancer drug market is expected to surpass US$ 150 Billion by 2028 which is mainly attributed to increase in prevalence of rare cancers associated with high demand for the orphan drugs in its management. The high spending on research and development of orphan cancer drugs, coupled with the presence of several large scale manufacturers are the major factoring driving the growth of market. Apart from this, several pharmaceutical companies like Amgen, Roche, Genetech have developed their assistance programs through which their potentially lower down the out-of pocket cost from the patients.

1. Research Methodology

2. Introduction To Orphan Drugs

3. Global Orphan Drug Designation Criteria

3.1 US
3.2 Europe
3.3 Asia & Australia

4. Market Exclusivity & Patent Protection for Orphan Drugs

5. Global Orphan Designated Cancer Drug Market

5.1 Current Market Scenario
5.2 Future Market Opportunity

6. Orphan Designated Cancer Drug Market Insight by Region

6.1 US
6.2 Europe
6.3 Japan
6.4 South Korea
6.5 China
6.6 Australia
6.7 UK
6.8 Canada
6.9 Middle East

7. Global Orphan Designated Cancer Drug Market by Indication

7.1 Lymphoma
7.2 Leukemia
7.3 Lung Cancer
7.4 Multiple Myeloma
7.5 Ovarian Cancer
7.6 Gastric Cancer
7.7 Thyroid Cancer
7.8 Liver Cancer
7.9 Pancreatic Cancer
7.10 Melanoma
7.11 Brain Cancer
7.12 Renal Cell Carcinoma

8. Top 50 Orphan Designated Cancer Drugs - Availability, Dosage, Price & Sales Forecats 2028

THIS CHAPTER GIVES COMPREHENISVE CLINICAL & COMMERCIAL INSIGHT ON TOP 50 ORPHAN DESIGNATED CANCER DRUGS. THESE DRUGS ACCOUNT FOR MORE THAN 70% OF TOTAL ORPHAN DESIGNATED CANCER DRUG MARKET. MORE THAN 500 CHARTS & GRAPHS REPRESENTING SALES, PATENT, PRICING, DOSAGE, APPROVAL YEAR INSIGHT ON TOP 50 ORPHNA DESIGNATED CANCER DRUGS.

9. Global Orphan Cancer Drugs Clinical Pipeline Overview

9.1 By Company
9.2 Drug Class
9.3 Indication
9.4 Priority Status
9.5 By Phase

10. Global Orphan Cancer Drugs Clinical Pipeline By Company, Country , Indication & Phase

10.1 Preclinical
10.2 Phase-I
10.3 Phase-I/II
10.4 Phase-II
10.5 Phase-II/III
10.6 Phase-III
10.7 Preregistration
10.8 Registered

11. Marketed Orphan Cancer Drugs Clinical Insight By Company, Country & Indication

12. Competitive Landscape

12.1 AOP Orphan
12.2 Agenus
12.3 Alexion
12.4 Bristol Myers Squibb
12.5 Biogen Idec
12.6 Celgene
12.7 Eli Lilly
12.8 Genethon
12.9 Genzyme Corporation
12.10 Glaxosmithkline
12.11 Merck
12.12 Novartis Pharmaceuticals
12.13 Orphan Europe
12.14 Pfizer
12.15 Prosensa
12.16 Rare Disease Therapeutics
12.17 Roche
12.18 Sanofi
12.19 Shire
12.20 Teva Pharmaceutical

List of Figures

Figure 5-1: Global - Rare vs. Other Cancer Prevalence (%)
Figure 5-2: Global - Top 10 Orphan Cancer Drug Sales (US$ Billion), 2021
Figure 5-3: Global - Sales of Orphan Cancer Drugs (US$ Billion), 2020 & 2021
Figure 5-4: Orphan Cancer Drugs - Sales Value by Region (US$ Billion), 2021
Figure 5-5: Orphan Cancer Drugs - Sales Value by Region (%), 2021
Figure 5-6: Global - Sales of Orphan Designated Cancer Drugs (US$ Billion), 2022 - 2028
Figure 6-1: US - Sales of Orphan Cancer Drugs (US$ Billion), 2020 & 2021
Figure 6-2: US vs. ROW - Sales of Orphan Cancer Drugs (US$ Billion), 2021
Figure 6-3: US vs. ROW - Sales of Orphan Cancer Drugs (%), 2021
Figure 6-4: US - Sales of Orphan Cancer Drugs (US$ Billion), 2022 - 2028
Figure 6-5: Europe - Orphan Drug Designation by Indication, 2021
Figure 6-6: Europe - Orphan Drug Designation by Indication (%), 2021
Figure 6-7: Europe - Sales of Orphan Cancer Drugs (US$ Billion), 2020 & 2021
Figure 6-8: Europe vs. ROW - Sales of Orphan Cancer Drugs (US$ Billion), 2021
Figure 6-9: Europe vs. ROW - Sales of Orphan Cancer Drugs (%), 2021
Figure 6-10: Europe - Sales of Orphan Cancer Drugs (US$ Billion), 2022 - 2028
Figure 6-11: Japan - Sales of Orphan Cancer Drugs (US$ Billion), 2020 & 2021
Figure 6-12: Japan vs. ROW - Sales of Orphan Cancer Drugs (US$ Billion), 2021
Figure 6-13: Japan vs. ROW - Sales of Orphan Cancer Drugs (%), 2021
Figure 6-14: Japan - Sales of Orphan Cancer Drugs (US$ Billion), 2022 - 2028
Figure 6-15: South Korea - Sales of Orphan Cancer Drugs (US$ Billion), 2020 & 2021
Figure 6-16: South Korea - Sales of Orphan Cancer Drugs (US$ Billion), 2022 - 2028
Figure 6-17: China - Sales of Orphan Cancer Drugs (US$ Billion), 2020 & 2021
Figure 6-18: China - Sales of Orphan Cancer Drugs (US$ Billion), 2022 - 2028
Figure 6-19: Australia - Average Incidences & Deaths of Rare Cancer
Figure 6-20: Australia - Sales of Orphan Cancer Drugs (US$ Billion), 2020 & 2021
Figure 6-21: Australia - Sales of Orphan Cancer Drugs (US$ Billion), 2022 - 2028
Figure 6-22: UK - Orphan Drug Designation by Indication, 2021
Figure 6-23: UK - Orphan Drug Designation by Indication (%), 2021
Figure 6-24: UK - Sales of Orphan Cancer Drugs (US$ Billion), 2020 & 2021
Figure 6-25: UK vs. ROW - Sales of Orphan Cancer Drugs (US$ Billion), 2021
Figure 6-26: UK vs. ROW - Sales of Orphan Cancer Drugs (%), 2021
Figure 6-27: UK - Sales of Orphan Cancer Drugs (US$ Billion), 2022 - 2028
Figure 6-28: Canada - Sales of Orphan Cancer Drugs (US$ Billion), 2020 & 2021
Figure 6-29: Canada - Sales of Orphan Cancer Drugs (US$ Billion), 2022 - 2028
Figure 6-30: Middle East - Sales of Orphan Cancer Drugs (US$ Billion), 2020 & 2021
Figure 6-31: Middle East - Sales of Orphan Cancer Drugs (US$ Billion), 2022 - 2028
Figure 7-1: Global - Sales of Orphan Designated Lymphoma Drugs (US$ Billion), 2021 - 2028
Figure 7-2: Global - Sales of Leukemia Designated Orphan Drugs (US$ Billion), 2021 - 2028
Figure 7-3: Global - Sales of Lung Cancer Designated Orphan Drugs (US$ Billion), 2021 - 2028
Figure 7-4: Global - Sales of Multiple Myeloma Designated Orphan Drugs (US$ Billion), 2021 - 2028
Figure 7-5: Global - Sales of Ovarian Cancer Designated Orphan Drugs (US$ Million), 2021 - 2028
Figure 7-6: Global - Sales of Gastric Cancer Designated Orphan Drugs (US$ Million), 2021 - 2028
Figure 7-7: Global - Sales of Thyroid Cancer Designated Orphan Drugs (US$ Million), 2021 - 2028
Figure 7-8: Global - Sales of Liver Cancer Designated Orphan Drugs (US$ Million), 2021 - 2028
Figure 7-9: Global - Sales of Pancreatic Cancer Designated Orphan Drugs (US$ Million), 2021 - 2028
Figure 7-10: Global - Sales of Melanoma Designated Orphan Drugs (US$ Million), 2021 - 2028
Figure 7-11: Global - Sales of Brain Cancer Designated Orphan Drugs (US$ Million), 2021 - 2028
Figure 7-12: Global - Sales of Renal Cell Carcinoma Designated Orphan Drugs (US$ Million), 2021 - 2028
Figure 8-1: Rituxan - FDA Approval Year by Indication
Figure 8-2: Rituxan - FDA Orphan Designation Year by Indication
Figure 8-3: Rituxan - Price for a Supply of 10 ml & Price Per ml of Injection (US$), June'2022
Figure 8-4: Rituxan - Price for a Supply of 50 ml & Price Per ml for Injection (US$), June'2022
Figure 8-5: Rituxan - Price for a Supply of 100 ml & Price Per ml for Injection (US$), June'2022
Figure 8-6: Rituxan Combination - Average Minimum & Maximum Cost for Refractory CD20+ B-Cell NHL Management (US$), June'2022
Figure 8-7: Rituxan Combination - Average Cost for Single Dose & Cost of Full Maintenance Phase for CLL (US$), June'2022
Figure 8-8: Rituxan - Value by Region (US$/CHF Million), Q1'2022
Figure 8-9: Global - Rituxan Sales Value (US$/CHF Million), 2018 - 2021
Figure 8-10: US - Rituxan Sales Value (US$/CHF Million), 2018 - 2021
Figure 8-11: Europe - Rituxan Sales Value (US$/CHF Million), 2018 - 2021
Figure 8-12: Japan - Rituxan Sales Value (US$/CHF Million), 2018 - 2021
Figure 8-13: ROW - Rituxan Sales Value (US$/CHF Million), 2018 - 2021
Figure 8-14: Rituxan - Sales Value by Region (US$/CHF Million), 2021
Figure 8-15: Rituxan - Sales Value by Region (%), 2021
Figure 8-16: Global - Rituximab Quarterly Sales Value (US$ Billion), 2021
Figure 8-17: Global - Rituxan Quarterly Sales Value (US$ Million), 2020
Figure 8-18: Global - Rituxan Sales Forecast (US$ Billion), 2022 - 2028
Figure 8-19: US - Rituxan Sales Forecast (US$ Billion), 2022 - 2028
Figure 8-20: Yervoy - US & Europe Exclusivity Expiration Year
Figure 8-21: Yervoy - FDA Orphan Designation Year by Indication
Figure 8-22: Yervoy - Price for 10ml Supply & Price Per ml of 5mg/ml Intravenous Injection (US$), June'2022
Figure 8-23: Yervoy - Price for 40ml Supply & Price Per ml 5mg/ml Intravenous Injection (US$), June'2022
Figure 8-24: Yervoy - Duration of Single Treatment Cycle & Full Treatment of Metastatic Melanoma & Hepatocellular Carcinoma (Weeks), June'2022
Figure 8-25: Yervoy - Average Cost of Single Treatment Cycle & Full Treatment of Metastatic Melanoma & Hepatocellular Carcinoma (US$), June'2022
Figure 8-26: Yervoy - Average Cost of Single Treatment Cycle, Initial Year & Remaining Years for Management of Metastatic Melanoma (US$), June'2022
Figure 8-27: Global - Yervoy Sales Value by Region (US$ Million), Q1'2022
Figure 8-28: Global - Yervoy Sales Value by Region (%), Q1'2022
Figure 8-29: Yervoy - Sales Value (US$ Billion), 2016-2021
Figure 8-30: Yervoy - Sales by Region (US$ Million), 2021
Figure 8-31: Yervoy - Sales by Region (US$ Million), 2021
Figure 8-32: Global - Yervoy Quarterly Sales Value (US$ Million), 2021
Figure 8-33: US - Yervoy Quarterly Sales Value (US$ Million), 2021
Figure 8-34: Global - Yervoy Quarterly Sales Value (US$ Million), 2020
Figure 8-35: Yervoy - Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 8-36: US - Yervoy Quarterly Sales Value (US$ Million), 2019
Figure 8-37: Yervoy - US v/s Rest of World Sales Share (%), 2019
Figure 8-38: Global - Yervoy Sales Forecast (US$ Million), 2022 - 2028
Figure 8-39: US - Yervoy Sales Forecast (US$ Million), 2022 - 2028
Figure 8-40: Opdivo - Patent Expiration Year by Region
Figure 8-41: Opdivo - US FDA Orphan Designation Year by Indication
Figure 8-42: Opdivo - Price for 4ml Supply & Price Per ml of 10mg/ml Intravenous Injection (US$), June'2022
Figure 8-43: Opdivo - Price for 10 ml Supply & Price Per ml of 10mg/ml Intravenous Injection (US$), June'2022
Figure 8-44: Opdivo - Price for 12 ml Supply & Price Per ml of 10mg/ml Intravenous Injection (US$), June'2022
Figure 8-45: Opdivo - Price for 24 ml Supply & Price Per ml of 10mg/ml Intravenous Injection (US$), June'2022
Figure 8-46: Opdivo Monotherapy Therapy - Single Treatment Cycle & Full Treatment Average Cost (US$), June'2022
Figure 8-47: Global - Opdivo Sales Value by Region (US$ Million), Q1'2022
Figure 8-48: Global - Opdivo Sales Value by Region (%), Q1'2022
Figure 8-49: Global - Opdivo Sales Value (US$ Million), 2016 - 2021
Figure 8-50: US - Opdivo Sales Value (US$ Million), 2016 - 2021
Figure 8-51: Opdivo - Sales by Region (US$ Million), 2021
Figure 8-52: Opdivo - Sales by Region (US$ Million), 2021
Figure 8-53: Global - Opdivo Quarterly Sales Value (US$ Million), 2021
Figure 8-54: US - Opdivo Quarterly Sales Value (US$ Million), 2021
Figure 8-55: Global - Opdivo Quarterly Sales Value (US$ Million), 2020
Figure 8-56: US - Opdivo Quarterly Sales Value (US$ Million), 2020
Figure 8-57: Global - Opdivo Sales Forecast (US$ Billion), 2022 - 2028
Figure 8-58: US - Opdivo Sales Forecast (US$ Billion), 2022 - 2028
Figure 8-59: Kyprolis - Proteolix Inc's Patents Issue & Expiration Year
Figure 8-60: Kyprolis - Cydex Pharmaceutical's Patent Issue & Expiration Year
Figure 8-61: Kyprolis - Issue & Expiration Year of Patents Assigned to Onyx Therapeutics
Figure 8-62: Kyprolis - Price of 10mg, 30mg & 60mg Intraveneous Powder for Injection (US$), June'2022
Figure 8-63: Kyprolis - Initial Dose & Maintainence Dose for Treatment of Multiple Myeloma (mg/m2 Per Week)
Figure 8-64: Kyprolis - Initial Dose & Maintainence Dose as Monotherapy for Treatment of Multiple Myeloma (mg/m2 Twice a Week)
Figure 8-65: Kyprolis - Sales by Region (US$ Million), Q1'2022
Figure 8-66: Kyprolis - Sales by Region (US$ Million), Q1'2022
Figure 8-67: Kyprolis - Sales Value (US$ Million), 2018 - 2021
Figure 8-68: Kyprolis - Sales by Region (US$ Million), 2021
Figure 8-69: Kyprolis - Sales by Region (US$ Million), 2021
Figure 8-70: Global - Kyprolis Quarterly Sales Value (US$ Million), 2021
Figure 8-71: US - Kyprolis Quarterly Sales Value (US$ Million), 2021
Figure 8-72: Global - Kyprolis Quarterly Sales Value (US$ Million), 2020
Figure 8-73: US - Kyprolis Quarterly Sales Value (US$ Million), 2020
Figure 8-74: Global - Kyprolis Sales Forecast (US$ Million), 2022 - 2028
Figure 8-75: US - Kyprolis Sales Forecast (US$ Million), 2022 - 2028
Figure 8-76: Revlimid - FDA Approval Year by Indication
Figure 8-77: Revlimid - FDA Approval & Patent Expiration Year
Figure 8-78: Revlimid - FDA Orphan Designation Year by Indication
Figure 8-79: Revlimid - Price for 28 capsules & 100 Capsules of 2.5mg, 5mg & 10mg Capsules (US$), June'2022
Figure 8-80: Revlimid - Price for 21 capsules & 100 Capsules of 15mg, 20mg & 25mg Capsules (US$), June'2022
Figure 8-81: Revlimid - Recommended Daily Dose by Indications (mg)
Figure 8-82: Revlimid - Sales by Region (US$ Million), Q1'2022
Figure 8-83: Revlimid - Sales by Region (US$ Million), Q1'2022
Figure 8-84: Global - Revlimid Sales Value (US$ Million), 2017 - 2021
Figure 8-85: US - Revlimid Sales Value (US$ Million), 2017 - 2021
Figure 8-86: Revlimid - Sales by Region (US$ Million), 2021
Figure 8-87: Revlimid - Sales by Region (US$ Million), 2021
Figure 8-88: Global - Revlimid Quarterly Sales Value (US$ Million), 2021
Figure 8-89: US - Revlimid Quarterly Sales Value (US$ Million), 2021
Figure 8-90: Global - Revlimid Quarterly Sales Value (US$ Million), 2020
Figure 8-91: US - Revlimid Quarterly Sales Value (US$ Million), 2020
Figure 8-92: Global - Revlimid Sales Forecast (US$ Billion), 2022 - 2028
Figure 8-93: US - Revlimid Sales Forecast (US$ Million), 2022 - 2028
Figure 8-94: Velcade - FDA Approval Year by Indication
Figure 8-95: Velcade - Patent Issue & Expiration Year
Figure 8-96: Velcade - US FDA Orphan Designation Year by Indication
Figure 8-97: Bortezomib - Generic Approval By Companies
Figure 8-98: Velcade - Minimum & Maximum Cost of Single Treatment Cycle (US$), June'2022
Figure 8-99: Velcade - Minimum & Maximum Cost of Single Treatment Cycle (US$), June'2022
Figure 8-100: Global - Velcade Sales Value (JPY/US$ Billion), 2017 - 2021
Figure 8-101: Global - Velcade Quarterly Sales Value (JPY/US$ Billion), Q1-Q3'2021
Figure 8-102: US - Velcade Sales Value (JPY/US$ Billion), 2018 - 2021
Figure 8-103: Global - Velcade Sales Value by Region (%), 2020
Figure 8-104: Global - Velcade Sales Forecast (US$ Million), 2022 - 2028
Figure 8-105: US - Velcade Sales Forecast (US$ Million), 2021-2026
Figure 8-106: Pomalyst - FDA Approval & Patent Expiration Year
Figure 8-107: Pomalyst - US FDA Orphan Designation Year by Indication
Figure 8-108: Pomalyst - Orphan Designation Year by Region
Figure 8-109: Pomalyst - Price for 21 Capsules Supply & Price per unit Capsule of Various Dose Regimens (US$), June'2022
Figure 8-110: Pomalyst - Price for 100 Capsules Supply & Price per unit Capsule of Various Dose Regimens (US$), June'2022
Figure 8-111: Pomalyst - Recommended Initial & Reduced Dose (mg/day)
Figure 8-112: Pomalyst - Sales by Region (US$ Million), Q1'2022
Figure 8-113: Pomalyst - Sales by Region (US$ Million), Q1'2022
Figure 8-114: Global - Pomalyst Sales Value (US$ Million), 2017 - 2021
Figure 8-115: Pomalyst - Sales by Region (US$ Million), 2021
Figure 8-116: Pomalyst - Sales by Region (US$ Million), 2021
Figure 8-117: Pomalyst - US v/s Rest of World Sales Value (US$ Million), 2020
Figure 8-118: Pomalyst - US v/s Rest of World Sales Value (%), 2020
Figure 8-119: Global - Pomalyst Quarterly Sales Value (US$ Million), 2021
Figure 8-120: US - Pomalyst Quarterly Sales Value (US$ Million), 2021
Figure 8-121: Global - Pomalyst Quarterly Sales Value (US$ Million), 2020
Figure 8-122: US - Pomalyst Quarterly Sales Value (US$ Million), 2020
Figure 8-123: Global - Pomalyst Sales Forecast (US$ Million), 2022 - 2028
Figure 8-124: US - Pomalyst Sales Forecast (US$ Million), 2022 - 2028
Figure 8-125: Sprycel - FDA Approval Year by Tablet Strength
Figure 8-126: Sprycel - Patent Issue & Expiration Year
Figure 8-127: Sprycel - US FDA Orphan Designation Issue & Exclusivity Expiration Year
Figure 8-128: Sprycel - Price for 60 Tablets & Price per Unit Tablet of 20mg, 50mg and 70mg (US$), June'2022
Figure 8-129: Sprycel - Price for 30 Tablets & Price per Unit Tablet of 80mg, 100mg and 140mg (US$), June'2022
Figure 8-130: Sprycel - Recommended Dose by Indication (mg/day)
Figure 8-131: Sprycel - Recommended Pediatric Dose by Weight (mg/day)
Figure 8-132: Sprycel - Sales by Region (US$ Million), Q1'2022
Figure 8-133: Sprycel - Sales by Region (US$ Million), Q1'2022
Figure 8-134: Global - Sprycel Sales Value (US$ Million), 2018 - 2021
Figure 8-135: US - Sprycel Sales Value (US$ Million), 2018 - 2021
Figure 8-136: Sprycel - Sales by Region (US$ Million), 2021
Figure 8-137: Sprycel - Sales by Region (US$ Million), 2021
Figure 8-138: Sprycel - US v/s Rest of World Sales Value (US$ Million), 2020
Figure 8-139: Sprycel - US v/s Rest of World Sales Value (%), 2020
Figure 8-140: Global - Sprycel Quarterly Sales Value (US$ Million), 2021
Figure 8-141: US - Sprycel Quarterly Sales Value (US$ Million), 2021
Figure 8-142: Global - Sprycel Quarterly Sales Value (US$ Million), 2020
Figure 8-143: Global - Sprycel Sales Forecast (US$ Million), 2022 - 2028
Figure 8-144: US - Sprycel Sales Forecast (US$ Million), 2022 - 2028
Figure 8-145: Imbruvica - FDA Approval Year by Indication
Figure 8-146: Imbruvica - FDA Orphan Designation Year by Indication
Figure 8-147: Imbruvica - FDA Approval Year by Dosage Form
Figure 8-148: Imbruvica - Approval Year by Region
Figure 8-149: Ibrutinib - Patent & Exclusivity Expiration Year
Figure 8-150: Imbruvica - Price for 90 & 120 Capsule Supplies of 140mg (US$), June'2022
Figure 8-151: Imbruvica Capsule - Price for 28 Capsule & Price Per unit Capsule of 70mg (US$), June'2022
Figure 8-152: Imbruvica Tablet - Price for 28 Tablets & Price Per unit Tablet of Various Doses (US$), June'2022
Figure 8-153: Imbruvica - Recommended Daily Dose by Indication (mg)
Figure 8-154: Imbruvica - Sales Value by Region (US$ Million), Q1'2022
Figure 8-155: Imbruvica - Sales Value by Region (%), Q1'2022
Figure 8-156: Imbruvica -Sales Value (US$ Billion), 2017 - 2021
Figure 8-157: Imbruvica - Sales Value by Region (US$ Million), 2021
Figure 8-158: Imbruvica - Sales Value by Region (%), 2021
Figure 8-159: Global - Imbruvica Quarterly Sales Value (US$ Million), 2021
Figure 8-160: US - Imbruvica Sales Value (US$ Billion), 2017 - 2021
Figure 8-161: US - Imbruvica Quarterly Sales Value (US$ Million), 2021
Figure 8-162: Global - Imbruvica Sales Forecast (US$ Billion), 2022 - 2028
Figure 8-163: US - Imbruvica Sales Forecast (US$ Billion), 2022 - 2028
Figure 8-164: Alimta - US FDA Approval & Orphan Designation
Figure 8-165: Alimta - FDA Approval Year by Dose Regimen
Figure 8-166: Alimta - Patent Issue & Expiration Year
Figure 8-167: Alimta - Price for 100mg & 500mg Intravenous Powder (US$), June'2022
Figure 8-168: Alimta - Treatment Cycle required in Combination with Pembrolizumab v/s Cisplatin
Figure 8-169: Alimta - Cost of Single Treatment Cycle & Full Treatment Cost of NSCLC (US$), June'2022
Figure 8-170: Alimta - US v/s Rest of World Sales Value (US$ Million), Q1'2022
Figure 8-171: Alimta - US v/s Rest of World Sales Value (%), Q1'2022
Figure 8-172: Global - Alimta Sales Value (US$ Billion), 2016 - 2021
Figure 8-173: Alimta - US v/s Rest of World Sales Value (US$ Million), 2021
Figure 8-174: Alimta - US v/s Rest of World Sales Value (%), 2021
Figure 8-175: Alimta - US v/s Rest of World Sales Value (US$ Million), 2020
Figure 8-176: Alimta - US v/s Rest of World Sales Value (%), 2020
Figure 8-177: Global - Alimta Quarterly Sales Value (US$ Million), 2021
Figure 8-178: US - Alimta Quarterly Sales Value (US$ Million), 2021
Figure 8-179: Global - Alimta Quarterly Sales Value (US$ Million), 2020
Figure 8-180: US - Alimta Quarterly Sales Value (US$ Million), 2020
Figure 8-181: Global - Alimta Sales Forecast (US$ Million), 2022 - 2028
Figure 8-182: US - Alimta Sales Forecast (US$ Million), 2022 - 2028
Figure 8-183: Tasigna - FDA Approval Year by Indication
Figure 8-184: Tasigna - Patent Issue & Expiration Year
Figure 8-185: Tasigna - Price for 120 Capsules & Price per unit Capsule of 50mg (US$), June'2022
Figure 8-186: Tasigna - Price for 28 Capsules & Price per unit Capsule of 150mg & 200mg (US$), June'2022
Figure 8-187: Tasigna - Price for 112 Capsules & Price per unit Capsule of 150mg & 200mg (US$), June'2022
Figure 8-188: Tasigna - Recommended Dose by Indication (mg Twice Daily)
Figure 8-189: Tasigna - Recommended Pediatric Dose by Surface Area (mg Twice Daily)
Figure 8-190: Global - Tasigna Quarterly Sales Value (US$ Million), Q1'2022 & Q1'2021
Figure 8-191: Global - Tasigna Sales Value (US$ Million), 2017 - 2021
Figure 8-192: Global - Tasigna Quarterly Sales Value (US$ Million), 2021
Figure 8-193: Global - Tasigna Quarterly Sales Value (US$ Million), 2020
Figure 8-194: Global - Tasigna Sales Forecast (US$ Million), 2022 - 2028
Figure 8-195: Keytruda - Patent Expiration Year by Region
Figure 8-196: Keytruda - US FDA Orphan Designation Year by Indication
Figure 8-197: US - Price for 4ml, 8ml Supply & Price Per ml of Keytruda Intravenous Injection (US$), June'2022
Figure 8-198: Keytruda - Duration of Single Treatment Cycle & Full Treatment of Melanoma & Other Cancers (Weeks)
Figure 8-199: Keytruda - Cost of Single & Full Treatment using Solution of Injection (US$), June'2022
Figure 8-200: Global - Keytruda Sales Value (US$ Million), Q1'2021 & Q1'2022
Figure 8-201: Global - Keytruda Sales Value (US$ Billion), 2018 - 2021
Figure 8-202: Global - Keytruda Quarterly Sales Value (US$ Billion), 2021
Figure 8-203: Global - Keytruda Quarterly Sales Value (US$ Billion), 2020
Figure 8-204: Global - Keytruda Sales Forecast (US$ Billion), 2022 - 2028
Figure 8-205: Avastin - Orphan Designation Year by Region
Figure 8-206: Avastin - US FDA Orphan Designation Year by Indication
Figure 8-207: Avastin - Price for a Supply of 10 & Price for Single 4ml Solution for Injection (US$), June'2022
Figure 8-208: Avastin - Price for a Supply of 10 & Price for Single 16ml Solution for Injection (US$), June'2022
Figure 8-209: Avastin - Cost of Single Treatment Cycle & Annual Treatment Cost for NSCLC & Metastatic Cervical Cancer (US$), June'2022
Figure 8-210: Avastin - Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$), June'2022
Figure 8-211: Avastin - Duration of Treatment of Recurrent Glioblastoma & Renal Cell Carcinoma as Combinational & Monotherapy (Weeks)
Figure 8-212: Avastin - Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$), June'2022
Figure 8-213: Avastin - Sales Value by Region (US$/CHF Million), Q1'2022
Figure 8-214: Avastin - Sales Value by Region (%), Q1'2022
Figure 8-215: Global - Avastin Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-216: US - Avastin Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-217: Europe - Avastin Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-218: Japan - Avastin Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-219: ROW - Avastin Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-220: Avastin - Sales Value by Region (US$/CHF Million), 2021
Figure 8-221: Avastin - Sales Value by Region (%), 2021
Figure 8-222: Global - Avastin Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-223: US - Avastin Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-224: Global - Avastin Sales Forecast (US$ Billion), 2022 - 2028
Figure 8-225: Tagrisso - Patent Issue & Expiration Year
Figure 8-226: Tagrisso - Price for 30 Tablet Supply & Price per unit of 200 mg Oral Tablet (US$), June'2022
Figure 8-227: Tagrisso - Recommended & Reduced Dose for NSCLC Treatment (mg per day)
Figure 8-228: Tagrisso - Sales Value by Region (US$ Million), Q1'2022
Figure 8-229: Tagrisso - Sales Value by Region (%), Q1'2022
Figure 8-230: Tagrisso - Sales Value (US$ Million), 2017 - 2021
Figure 8-231: Tagrisso - Sales Value by Region (US$ Million), 2021
Figure 8-232: Tagrisso - Sales Value by Region (%), 2021
Figure 8-233: Tagrisso - Sales Value by Region (US$ Million), 2020
Figure 8-234: Tagrisso - Sales Value by Region (%), 2020
Figure 8-235: Global - Tagrisso Quarterly Sales Value (US$ Million), 2021
Figure 8-236: Global - Tagrisso Quarterly Sales Value (US$ Million), 2020
Figure 8-237: Global - Tagriso Sales Forecast (US$ Million), 2022 - 2028
Figure 8-238: US - Tagriso Sales Forecast (US$ Million), 2022 - 2028
Figure 8-239: Europe - Tagriso Sales Forecast (US$ Million), 2022 - 2028
Figure 8-240: Herceptin - Approval Year by Cancer Type
Figure 8-241: Herceptin - Orphan Designation Year by Indication
Figure 8-242: Herceptin - Price for a Supply of 10 & Price for Single 150mg Powder for Injection (US$), June'2022
Figure 8-243: Herceptin - Initial & Maintenance Dose for Breast Cancer Treatment (mg/kg)
Figure 8-244: Herceptin - Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Breast Cancer (US$), March'2022
Figure 8-245: Herceptin - Initial & Maintenance Dose for Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (mg/kg)
Figure 8-246: Herceptin - Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (US$), March'2022
Figure 8-247: Herceptin - Sales Value by Region (US$/CHF Million), Q1'2022
Figure 8-248: Herceptin - Sales Value by Region (%), Q1'2022
Figure 8-249: Global - Herceptin Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-250: US - Herceptin Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-251: Europe - Herceptin Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-252: Japan - Herceptin Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-253: ROW - Herceptin Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-254: Herceptin - Sales Value by Region (US$/CHF Million), 2021
Figure 8-255: Herceptin - Sales Value by Region (%), 2021
Figure 8-256: Global - Herceptin Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-257: US - Herceptin Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-258: Global - Hercepin Sales Forecast (US$ Million), 2022 - 2028
Figure 8-259: Darzalex - FDA Approval & Patent Expiration Year
Figure 8-260: Darzalex - FDA Orphan Designation Year by Indication
Figure 8-261: Darzalex - EMA Orphan Designation Year by Indication
Figure 8-262: Darzalex - Price for 5 ml Supply & Price per ml of 20mg/ml Intravenous Solution (US$), June'2022
Figure 8-263: Darzalex - Price for 20 ml Supply & Price per ml of 20mg/ml Intravenous Solution (US$), June'2022
Figure 8-264: Darzalex - Duration of Dose Interval by Treatment Phase (Weeks)
Figure 8-265: Darzalex - Sales Value by Region (US$ Million), Q1'2022
Figure 8-266: Darzalex - Sales Value by Region (%), Q1'2022
Figure 8-267: Global - Darzalex Sales Value (US$ Million), 2017 - 2021
Figure 8-268: US - Darzalex Sales Value (US$ Million), 2017 - 2021
Figure 8-269: Darzalex - Sales Value by Region (US$ Million), 2021
Figure 8-270: Darzalex - Sales Value by Region (%), 2021
Figure 8-271: Darzalex - Sales by Region (%), 2019
Figure 8-272: Darzalex - Sales Value by Region (%), 2020
Figure 8-273: Global - Darzalex Quarterly Sales Value (US$ Million), 2021
Figure 8-274: US - Darzalex Quarterly Sales Value (US$ Million), 2021
Figure 8-275: Global - Darzalex Quarterly Sales Value (US$ Million), 2020
Figure 8-276: US - Darzalex Quarterly Sales Value (US$ Million), 2019
Figure 8-277: US - Darzalex Quarterly Sales Value (US$ Million), 2020
Figure 8-278: Global - Darzalex Sales Forecast (US$ Billion), 2022 - 2028
Figure 8-279: US - Darzalex Sales Forecast (US$ Million), 2022 - 2028
Figure 8-280: Venclexta - Approval Year by Region
Figure 8-281: Venclexta - FDA Approval Year by Indication
Figure 8-282: Venclexta - FDA Orphan Designation Year by Indication
Figure 8-283: Venclexta - Orphan Designation Year by Region
Figure 8-284: Venetoclax - Patent Issue & Expiration year
Figure 8-285: Venclexta - Price for 2 Tablet Supply & Price per unit Tablet of 10mg (US$), June'2022
Figure 8-286: Venclexta - Price for 14 Tablet Supply & Price per unit Tablet of 10mg (US$), June'2022
Figure 8-287: Venclexta - Price for Various Supplies of 50mg Tablet (US$), June'2022
Figure 8-288: Venclexta - Price for 120 Tablet Supply & Price per unit Tablet of 100mg (US$), June'2022
Figure 8-289: Venclexta - Price for 180 Tablet Supply & Price per unit Tablet of 100mg (US$), June'2022
Figure 8-290: Venclexta - Price for 42 Kit & Price per unit Kit (US$), June'2022
Figure 8-291: Venetoclax Monotherapy - Recommended Dose by Treatment Week for CLL Management (mg/day)
Figure 8-292: Venetoclax Combinational - Recommended Dose in Initial & Subsequent Treatment Cycle for CLL (mg/Cycle)
Figure 8-293: Venetoclax Monotherapy - Recommended Dose for AML (mg/day)
Figure 8-294: Venclexta - Sales Value by Region (US$ Million), Q1'2022
Figure 8-295: Venclexta - Sales Value by Region (%), Q1'2022
Figure 8-296: Global - Venclexta Sales Value (US$ Million), 2018 - 2021
Figure 8-297: US - Venclexta Sales Value (US$ Million), 2018 - 2021
Figure 8-298: Venclexta - Sales Value by Region (US$ Million), 2021
Figure 8-299: Venclexta - Sales Value by Region (%), 2021
Figure 8-300: Venclexta - Sales Value by Region (US$ Million), 2020
Figure 8-301: Venclexta - Sales Value by Region (%), 2020
Figure 8-302: Global - Venclexta Quarterly Sales Value (US$ Million), 2021
Figure 8-303: US - Venclexta Quarterly Sales Value (US$ Million), 2021
Figure 8-304: Global - Venclexta Quarterly Sales Value (US$ Million), 2020
Figure 8-305: US - Venclexta Quarterly Sales Value (US$ Million), 2020
Figure 8-306: Global - Venclexta Sales Forecast (US$ Million), 2022 - 2028
Figure 8-307: US - Venclexta Sales Forecast (US$ Million), 2022 - 2028
Figure 8-308: Tecentriq - FDA Approval & Patent Expiration Year
Figure 8-309: Tecentriq - FDA Orphan Designation Year by Indication
Figure 8-310: Tecentriq - Price for 14ml Supply & Price Per ml of 840mg/14ml Intravenous Injection (US$), June'2022
Figure 8-311: Tecentriq - Price for 20ml Supply & Price Per ml of 1200mg/20ml Intravenous Injection (US$), June'2022
Figure 8-312: Tecentriq - Average Cost of Single Treatment Cycle & Annual Treatment using 840mg/2 Week Dose (US$), June'2022
Figure 8-313: Tecentriq - Average Cost of Single Treatment Cycle & Annual Treatment using 1200mg/3 Week Dose (US$), June'2022
Figure 8-314: Tecentriq - Average Cost of Single Treatment Cycle & Annual Treatment using 1680mg/4 Week Dose (US$), June'2022
Figure 8-315: Tecentriq - Sales Value by Region (US$/CHF Million), Q1'2022
Figure 8-316: Tecentriq - Sales Value by Region (%), Q1'2022
Figure 8-317: Global - Tecentriq Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-318: US - Tecentriq Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-319: Europe - Tecentriq Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-320: Japan - Tecentriq Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-321: ROW - Tecentriq Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-322: Tecentriq - Sales Value by Region (US$/CHF Million), 2021
Figure 8-323: Tecentriq - Sales Value by Region (%), 2021
Figure 8-324: Global - Tecentriq Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-325: US - Tecentriq Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-326: US - Tecentriq Quarterly Sales Value (US$/CHF Million), 2020
Figure 8-327: Global - Tecentriq Sales Forecast (US$ Million), 2022 - 2028
Figure 8-328: US - Tecentriq Sales Forecast (US$ Million), 2022 - 2028
Figure 8-329: Europe - Tecentriq Sales Forecast (US$ Million), 2022 - 2028
Figure 8-330: Japan - Tecentriq Sales Forecast (US$ Million), 2022 - 2028
Figure 8-331: ROW - Tecentriq Sales Forecast (US$ Million), 2022 - 2028
Figure 8-332: Kadcyla - FDA Approval Year for Late Stage & Early Stage HER2+ Breast Cancer
Figure 8-333: Kadcyla - Patent Expiration Year by Region
Figure 8-334: US - Price for Single Unit of Kadcyla 100mg & 160mg Intravenous Powder for Injection (US$), June'2022
Figure 8-335: Kadcyla - Duration of Single Treatment Cycle & Full Treatment of Early Stage HER2+ Breast Cancer (Weeks)
Figure 8-336: Kadcyla - Recommended Dose After 1st & 2nd Dose Reduction (mg/m2)
Figure 8-337: Global - Kadcyla Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-338: US - Kadcyla Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-339: Europe - Kadcyla Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-340: Japan - Kadcyla Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-341: ROW - Kadcyla Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-342: Kadcyla - Sales Value by Region (US$/CHF Million), 2021
Figure 8-343: Kadcyla - Sales Value by Region (%), 2021
Figure 8-344: Global - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-345: US - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-346: Europe - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-347: Japan - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-348: ROW - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-349: Global - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
Figure 8-350: US - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
Figure 8-351: Europe - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
Figure 8-352: Japan - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
Figure 8-353: ROW - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
Figure 8-354: Kadcyla - Sales Value by Region (US$/CHF Million), 2020
Figure 8-355: Kadcyla - Sales Value by Region (%). 2020
Figure 8-356: Global - Kadcyla Quarterly Sales Value (US$/CHF Million), 2019
Figure 8-357: US - Kadcyla Quarterly Sales Value (US$/CHF Million), 2019
Figure 8-358: Europe - Kadcyla Quarterly Sales Value (US$/CHF Million), 2019
Figure 8-359: Japan - Kadcyla Quarterly Sales Value (US$/CHF Million), 2019
Figure 8-360: ROW - Kadcyla Quarterly Sales Value (US$/CHF Million), 2019
Figure 8-361: Kadcyla - Sales Value by Region (US$/CHF Million), 2019
Figure 8-362: Global - Kadcyla Sales Forecast (US$ Million), 2022 - 2028
Figure 8-363: US - Kadcyla Sales Forecast (US$ Million), 2022 - 2028
Figure 8-364: Europe - Kadcyla Sales Forecast (US$ Million), 2022 - 2028
Figure 8-365: Japan - Kadcyla Sales Forecast (US$ Million), 2022 - 2028
Figure 8-366: ROW - Kadcyla Sales Forecast (US$ Million), 2022 - 2028
Figure 8-367: Imfinzi - FDA Approval & Patent Expiration Year
Figure 8-368: Imfinzi - FDA Approval Year by Indication
Figure 8-369: Imfinzi - FDA Orphan Designation & Exclusivity Expiration Year
Figure 8-370: US- Price for a Supply of 2.4ml & Price Per ml of Imfinzi Solution for Injection (US$), June'2022
Figure 8-371: US - Price for a Supply of 10 ml & Price Per ml of Imfinzi Solution for Injection (US$), June'2022
Figure 8-372: Imfinzi Combination Therapy - Single Treatment Cycle & Full Treatment Average Cost (US$), June'2022
Figure 8-373: Imfinzi - Sales Value by Region (US$ Million), Q1'2022
Figure 8-374: Imfinzi - Sales Value by Region (US$ Million), Q1'2022
Figure 8-375: Global - Imfinzi Sales Value (US$ Million), 2017 - 2021
Figure 8-376: US - Imfinzi Sales Value (US$ Million), 2019 - 2021
Figure 8-377: Europe - Imfinzi Sales Value (US$ Million), 2019 - 2021
Figure 8-378: Imfinzi - Sales Value by Region (US$ Million), 2021
Figure 8-379: Imfinzi - Sales Value by Region (%), 2021
Figure 8-380: Global - Imfinzi Sales Value by Region (US$ Million), 2020
Figure 8-381: Global - Imfinzi Sales Value by Region (%), 2020
Figure 8-382: Global - Imfinzi Quarterly Sales Value (US$ Million), 2020
Figure 8-383: Global - Imfinzi Quarterly Sales Value (US$ Million), 2020
Figure 8-384: US - Imfinzi Quarterly Sales Value US$ Million), 2021
Figure 8-385: US - Imfinzi Quarterly Sales Value US$ Million), 2020
Figure 8-386: Global - Imfinzi Sales Forecast (US$ Million), 2022 - 2028
Figure 8-387: US - Imfinzi Sales Forecast (US$ Million), 2022 - 2028
Figure 8-388: Europe - Imfinzi Sales Forecast (US$ Million), 2022 - 2028
Figure 8-389: ROW - Imfinzi Sales Forecast (US$ Million), 2022 - 2028
Figure 8-390: Lynparza - FDA Approval Year by Indication
Figure 8-391: Lynparza - FDA Orphan Designation Year by Indication
Figure 8-392: Lynparza - Orphan Designation Year by Region
Figure 8-393: Lynparza - Number of Patent Issued by Assignee Name
Figure 8-394: Lynparza - Patent Expiration Year by Assignee
Figure 8-395: Lynparza - Price for 60 & 120 Tablet Supply & Price per Unit Tablet (US$), June'2022
Figure 8-396: Lynparza - Recommended Dose & Dose after Reduction (mg/day)
Figure 8-397: Global - Lynparza Sales Value (US$ Million), 2017 - 2021
Figure 8-398: Lynparza - Value by Region (US$ Million), 2021
Figure 8-399: Lynparza - Sales Value by Region (%), 2021
Figure 8-400: Lynparza - Sales Value by Region (US$ Million), 2020
Figure 8-401: Lynparza - Sales Value by Region (%), 2020
Figure 8-402: Lynparza - Sales Value by Region (US$ Million), 2019
Figure 8-403: Lynparza - Sales Value by Region (%), 2019
Figure 8-404: Global - Lynparza Quarterly Sales (US$ Million), 2021
Figure 8-405: Global - Lynparza Quarterly Sales (US$ Million), 2020
Figure 8-406: Global - Lynpraza Sales Forecast (US$ Million), 2022 - 2028
Figure 8-407: US - Lynpraza Sales Forecast (US$ Million), 2022 - 2028
Figure 8-408: Europe - Lynpraza Sales Forecast (US$ Million), 2022 - 2028
Figure 8-409: Cyramza - Approval Year by Region
Figure 8-410: US - Cyramza FDA Approval History by Indication
Figure 8-411: US - Cyramza Orphan Drug Designation by Indication
Figure 8-412: US - Cyramza Patent Approval & Expiration Year
Figure 8-413: Cyramza - Patent Exclusivity by Region
Figure 8-414: Cyramza - Cost of 10ml & Per unit Price of 10mg/ml Intravenous Solution (US$), June'2022
Figure 8-415: Cyramza - Cost of 50ml & Per unit Price of 10mg/ml Intravenous Solution (US$), June'2022
Figure 8-416: Ramucirumab - Recommended Dosage by Indication (mg/kg)
Figure 8-417: Global - Cyramza Sales (US$ Million) by Region, Q1'2022 & Q1'2021
Figure 8-418: Global - Cyramza Sales (US$ Million), 2017 - 2021
Figure 8-419: US - Cyramza Sales (US$ Million), 2017 - 2021
Figure 8-420: Global - Cyramza Sales (US$ Million) by Region, 2021
Figure 8-421: Global - Cyramza Sales (%) by Region, 2021
Figure 8-422: Global - Cyramza Sales (US$ Million) by Region, 2020
Figure 8-423: Global - Cyramza SalesValue (%) by Region, 2020
Figure 8-424: Global - Cyramza Quarterly Sales (US$ Million), 2021 & 2020
Figure 8-425: Global - Cyramza Sales Forecast (US$ Million), 2022 - 2028
Figure 8-426: US - Cyramza Sales Forecast (US$ Million), 2022 - 2028
Figure 8-427: ROW - Cyramza Sales Forecast (US$ Million), 2022 - 2028
Figure 8-428: Imatinib - Approval Year by Region
Figure 8-429: US - Gleevec FDA Approval History by Indication
Figure 8-430: US - Gleevec Orphan Drug Designation by Therapeutic Indication
Figure 8-431: US - Gleevec Patent Approval & Expiration Year
Figure 8-432: Imatinib - 1st Generic Approval by Region
Figure 8-433: Gleevec - Cost of Supply of 90 Tablets & Per Unit Cost of 100mg Oral Tablet (US$), June'2022
Figure 8-434: Gleevec - Cost of Supply of 30 Tablets & Per Unit Cost of 400mg Oral Tablet (US$), June'2022
Figure 8-435: Imatinib - Cost of Supply of 20 Tablets & Per Unit Cost of 100mg Oral Tablet (US$), June'2022
Figure 8-436: Imatinib - Cost of Supply of 30 Tablets & Per Unit Cost of 100mg Oral Tablet (US$), June'2022
Figure 8-437: Imatinib - Cost of Supply of 90 Tablets & Per Unit Cost of 100mg Oral Tablet (US$), June'2022
Figure 8-438: Imatinib - Cost of Supply of 20 Tablets & Per Unit Cost of 400mg Oral Tablet (US$), June'2022
Figure 8-439: Imatinib - Cost of Supply of 30 Tablets & Per Unit Cost of 400mg Oral Tablet (US$), March'2022
Figure 8-440: Imatinib - Recommended Initial Dose in Adult by Therapeutic Condition (mg/day)
Figure 8-441: Global - Gleevec/Glivec Sales (US$ Million), Q1'2022 & Q1'2021
Figure 8-442: Global - Gleevec/Glivec Sales Value (US$ Million), 2018-2021
Figure 8-443: Global - Gleevec/Glivec Quarterly Sales (US$ Million), 2021
Figure 8-444: Global - Gleevec/Glivec Quarterly Sales (US$ Million), 2019 & 2020
Figure 8-445: Global - Glivec/Gleevec Sales Forecast (US$ Million), 2022 - 2028
Figure 8-446: Abraxane - Approval Year by Region
Figure 8-447: US - Abraxane FDA Approval Year by Indication
Figure 8-448: Abraxane - FDA Approval Year & Orphan Drug Designation for Pancreatic Cancer
Figure 8-449: US - Abraxane Patent Approval & Expiration Year
Figure 8-450: Abraxane - Patent Exclusivity by Region
Figure 8-451: Abraxane - EMA Approval & Generic Approval Year
Figure 8-452: Abraxane - Recommended Initial Dose by Indication (mg/m2)
Figure 8-453: Abraxane - Cost of 1 Cycle & Annual Treatment Cost for Breast Cancer (US$), June'2022
Figure 8-454: Abraxane - Cost of 1 Cycle & Annual Treatment Cost for NSCLC (US$), June'2022
Figure 8-455: Abraxane - Cost of 1 Cycle & Annual Treatment Cost for Pancreatic Cancer (US$), June'2022
Figure 8-456: Abraxane - Sales by Region (US$ Million), Q1'2022
Figure 8-457: Abraxane - Sales by Region (%),Q1'2022
Figure 8-458: Global - Abraxane Sales Value (US$ Million), 2019 - 2021
Figure 8-459: US - Abraxane Sales Value (US$ Million), 2019 - 2021
Figure 8-460: Abraxane - Sales Value by Region (US$ Million), 2021
Figure 8-461: Abraxane - Sales Value by Region (%), 2021
Figure 8-462: Global - Abraxane Quaterly Sales (US$ Million), 2021
Figure 8-463: Global - Abraxane Quaterly Sales (US$ Million), 2020
Figure 8-464: US - Abraxane Quaterly Sales (US$ Million), 2021
Figure 8-465: US - Abraxane Quaterly Sales (US$ Million), 2020
Figure 8-466: Global - Abraxane Sales Forecast (US$ Million), 2022 - 2028
Figure 8-467: US - Abraxane Sales Forecast (US$ Million), 2022 - 2028
Figure 8-468: Polivy - Orphan Drug Designation Approval Year by Region
Figure 8-469: US - Polivy Orphan Drug Designation Approval & Exclusivity Year
Figure 8-470: Polivy - Approval Year by Region
Figure 8-471: Polivy - Price for Single Unit of 30mg & 140mg Intravenous Powder for Injection (US$), June'2022
Figure 8-472: Polivy - Duration of Single Treatment Cycle & Full Treatment (Weeks)
Figure 8-473: Polivy - Cost of Single Dose, Single Treatment Cycle & Full Treatment of DLBCL (US$), June'2022
Figure 8-474: Polivy - Sales Value by Region (US$/CHF Million), Q1'2022
Figure 8-475: Global - Polivy Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-476: Global - Polivy Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-477: US - Polivy Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-478: Europe - Polivy Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-479: Japan - Polivy Quarterly Sales Value (US$/CHF Million), Q2-Q4'2021
Figure 8-480: ROW - Polivy Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-481: Polivy - Sales Value by Region (US$/CHF Million), 2021
Figure 8-482: Polivy - Sales Value by Region (%), 2021
Figure 8-483: Global - Polivy Quarterly Sales Value (US$/CHF Million), 2020
Figure 8-484: US - Polivy Quarterly Sales Value (US$/CHF Million), 2020
Figure 8-485: Europe - Polivy Quarterly Sales Value (US$/CHF Million), 2020
Figure 8-486: Polivy - Sales Value by Region (US$/CHF Million), 2020
Figure 8-487: Polivy - Sales Value by Region (%), 2020
Figure 8-488: Polivy - Quarterly Sales Value (US$/CHF Million), Q2-Q4'2019
Figure 8-489: Global - Polivy Sales Forecast (US$ Million), 2022 - 2028
Figure 8-490: US - Polivy Sales Forecast (US$ Million), 2022 - 2028
Figure 8-491: Europe - Polivy Sales Forecast (US$ Million), 2022 - 2028
Figure 8-492: Japan - Polivy Sales Forecast (US$ Million), 2022 - 2028
Figure 8-493: ROW - Polivy Sales Forecast (US$ Million), 2022 - 2028
Figure 8-494: US - Adcetris Orphan Drug Designation Approval Year by Indication
Figure 8-495: Europe - Adcetris Orphan Drug Designation Approval Year by Indication
Figure 8-496: Adcetris - Orphan Drug Designation Approval Year by Region
Figure 8-497: US - Adcetris FDA Approval Year by Indication
Figure 8-498: Adcetris - Approval Year by Region
Figure 8-499: Japan - Adcetris FDA Approval Year by Indication
Figure 8-500: Adcetris - Patent Expiration by Region
Figure 8-501: Adcetris - Duration of Single Treatment Cycle & Full Treatment of Stage III and IV Classical Hodgkin Lymphoma (Weeks)
Figure 8-502: Adcetris - Maximum Cost of Single Treatment Cycle & Full Treatment of Stage III and IV Classical Hodgkin Lymphoma (US$), June'2022
Figure 8-503: Adcetris - Duration of Single Treatment Cycle & Full Treatment of Classical Hodgkin Lymphoma (Weeks)
Figure 8-504: Adcetris - Maximum Cost of Single Treatment Cycle & Full Treatment of Classical Hodgkin Lymphoma (US$), June'2022
Figure 8-505: Adcetris - Maximum Cost of Single Treatment Cycle & Full Treatment of Previously Untreated Systemic ALCL or Other CD30 T-Cell Lymphomas (US$), June'2022
Figure 8-506: Adcetris - Duration of Single Treatment Cycle & Full Treatment of Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (Weeks)
Figure 8-507: Adcetris - Maximum Cost of Single Treatment Cycle & Full Treatment of Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (US$), June'2022
Figure 8-508: Global - Adcetris Sales Value (US$ Million), Q1'2021 & Q1'2022
Figure 8-509: Global - Adcetris Sales Value (US$ Million), 2018 - 2021
Figure 8-510: Global - Adcetris Quarterly Sales Value (US$ Million), 2021
Figure 8-511: Global - Adcetris Quarterly Sales Value (US$ Million), 2020
Figure 8-512: US - Enhertu Orphan Drug Designation Approval & Exclusivity Year
Figure 8-513: Enhertu - Approval Year by Region
Figure 8-514: US - Polivy FDA Approval Year by Indication
Figure 8-515: Enhertu - Recommended Dose by Cancer Type (mg/Kg)
Figure 8-516: Enhertu - Average Cost of Single Treatment Cycle & Annual Treatment Cost (US$), June'2022
Figure 8-517: Enhertu - Recommended Dose & Dose after Reduction for Breast Cancer (mg/Kg)
Figure 8-518: Enhertu - Recommended Dose & Dose after Reduction for Gastric Cancer (mg/Kg)
Figure 8-519: Global - Enhertu Sales Value by Region (US$ Million), Q1'2022
Figure 8-520: Global - Enhertu Sales Value (US$ Million), 2020 & 2021
Figure 8-521: Global - Enhertu Quarterly Sales (US$ Million), 2021
Figure 8-522: Global - Enhertu Quarterly Sales (US$ Million), 2020
Figure 8-523: Global - Enhertu Sales Forecast (US$ Million), 2022 - 2028
Figure 8-524: US - Blenrep FDA Orphan Drug Designation & Approval Year
Figure 8-525: US - Blenrep FDA Orphan Drug Designation Approval & Patent Exclusivity Year
Figure 8-526: Europe - Blenrep FDA Orphan Drug Designation & Approval Year
Figure 8-527: Blenrep - Average Cost of Single Treatment Cycle & Annual Treatment Cost (US$), June'2022
Figure 8-528: Blenrep - Recommended Dose & Dose after Reduction (mg/Kg)
Figure 8-529: Blenrep - Sales by Region (Euro/US$ Million), Q1'2022
Figure 8-530: Blenrep - Sales by Region (%), Q1'2022
Figure 8-531: Global - Blenrep Sales Value (US$ Million), 2020 & 2021
Figure 8-532: Global - Blenrep Quarterly Sales (Euro/US$ Million), 2021
Figure 8-533: US - Blenrep Quarterly Sales (Euro/US$ Million), 2021
Figure 8-534: Europe - Blenrep Quarterly Sales (Euro/US$ Million), 2021
Figure 8-535: Blenrep - Sales Value by Region (Euro/US$ Million), 2021
Figure 8-536: Blenrep - Sales Value by Region (%), 2021
Figure 8-537: Global - Blenrep Quarterly Sales (Euro/US$ Million), Q3 & Q4'2020
Figure 8-538: Global - Blenrep Sales Value (US$ Million), 2022 - 2028
Figure 8-539: US - Blenrep Sales Value (US$ Million), 2022 - 2028
Figure 8-540: Europe - Blenrep Sales Value (US$ Million), 2022 - 2028
Figure 8-541: ROW - Blenrep Sales Value (US$ Million), 2022 - 2028
Figure 8-542: US - Zynlonta FDA Orphan Drug Designation Approval & Patent Exclusivity Year
Figure 8-543: US - Zynlonta Orphan Drug Designation & FDA Approval Year
Figure 8-544: Zynlonta - Orphan Drug Designation by Region
Figure 8-545: Zynlonta - Average Cost of Single Treatment Cycle & Annual Treatment Cost (US$), June'2022
Figure 8-546: Zynlonta - Recommended Dose for Initial & Subsequent Cycles (mg/kg)
Figure 8-547: Global - Zynlonta Quarterly Sales (US$ Million), Q2 -Q4'2021
Figure 8-548: Global - Zynlonta Sales Forecast (US$ Million), 2022 - 2028
Figure 8-549: US - Bavencio Orphan Drug Designation Approval & Exclusivity Year
Figure 8-550: Bavencio - FDA Approval Year by Indication
Figure 8-551: Bavencio - Price for 10ml Supply & Price Per ml of 20mg/ml Intravenous Injection (US$), June'2022
Figure 8-552: Bavencio - Average Cost of Single Treatment Cycle & Annual Treatment (US$), June'2022
Figure 8-553: Global - Bavencio Sales Value (US$ Million), 2020 & 2021
Figure 8-554: US - Bavencio Sales Value (US$ Million), 2020 & 2021
Figure 8-555: Europe - Bavencio Sales Value (US$ Million), 2020 & 2021
Figure 8-556: Bavencio - Sales Value by Region (US$ Million), 2021
Figure 8-557: Bavencio - Sales Value by Region (%), 2021
Figure 8-558: Global - Bavencio Sales Forecast (US$ Million), 2022 - 2028
Figure 8-559: US - Bavencio Sales Forecast (US$ Million), 2022 - 2028
Figure 8-560: Europe - Bavencio Sales Forecast (US$ Million), 2022 - 2028
Figure 8-561: ROW - Bavencio Sales Forecast (US$ Million), 2022 - 2028
Figure 8-562: Iclusig - Orphan Drug Designation by Region
Figure 8-563: Iclusig - Approval Year by Region
Figure 8-564: US - Iclusig Approval by Indication
Figure 8-565: US - Iclusig Patent Approval & Expiration Year
Figure 8-566: Europe - Iclusig EMA Approval & Patent Exclusivity Year
Figure 8-567: Japan - Iclusig Approval & Patent Exclusivity Year
Figure 8-568: Iclusig - Cost of Supply of 30 Tablets & Per Unit Cost of Oral Tablet (US$), June'2022
Figure 8-569: Ponatinib - Initial & Dose Reductions for CP-CML (mg/day)
Figure 8-570: Ponatinib - Initial & Dose Reductions for Resistant CML & Ph+ ALL (mg/day)
Figure 8-571: Global - Inclusig Sales Value (US$ Million), Q1'2021 & Q1'2022
Figure 8-572: Global - Inclusig Sales Value (US$ Million), 2017-2021
Figure 8-573: Global - Inclusig Quarterly Sales (US$ Million), 2021
Figure 8-574: Global - Inclusig Quarterly Sales (US$ Million), 2019 & 2020
Figure 8-575: Global - Iclusig Sales Forecast (US$ Million), 2022-2028
Figure 8-576: US - Lumakras Orphan Drug Designation Approval & Exclusivity Year
Figure 8-577: Lumakras - Approval Year by Region
Figure 8-578: US - Lumakras Patent Expiration Year
Figure 8-579: US - Lumakras FDA Approval & Patent Exclusivity Year
Figure 8-580: Lumakras - Price for 240 Tablet Supply & Price Per Unit of 120mg Tablet (US$), June'2022
Figure 8-581: US - Monthly & Annual Treatment Cost with Lumakras (US$), June'2022
Figure 8-582: Lumakras - Recommended Initial & Reduced Dose (mg/day)
Figure 8-583: Global - Lumakras/Lumykras Sales by Region (US$ Million), Q1'2022
Figure 8-584: Global - Lumakras/Lumykras Sales by Region (%),Q1'2022
Figure 8-585: Global - Lumakras/Lumykras Sales by Region (US$ Million), 2021
Figure 8-586: Global - Lumakras/Lumykras Sales by Region (%), 2021
Figure 8-587: Global - Lumakras/Lumykras Quarterly Sales (US$ Million), Q2- Q4'2021
Figure 8-588: US - Lumakras/Lumykras Quarterly Sales (US$ Million), Q2-Q4'2021
Figure 8-589: ROW - Lumakras/Lumykras Quarterly Sales (US$ Million), Q3 & Q4'2021
Figure 8-590: Global - Lumakras Sales Forecast (US$ Million), 2022 - 2028
Figure 8-591: US - Lumakras Sales Forecast (US$ Million), 2022 - 2028
Figure 8-592: Iclusig - Orphan Drug Designation by Region
Figure 8-593: Iclusig - FDA Approval Year by Region
Figure 8-594: Blincyto - Number of Induction & Consolidation Cycles for Treatment of MRD+ B-cell precursor ALL
Figure 8-595: Blincyto - Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD+ B-cell Precursor ALL (Days)
Figure 8-596: Blincyto - Cost of Single Cycle & Full Treatment Cost of MRD+ B-cell precursor ALL (US$), June'2022
Figure 8-597: Blincyto - Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL
Figure 8-598: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks)
Figure 8-599: Blincyto - Cost of 1st & 2nd Induction Cycle for Treatment of Relapsed B-Cell Precursor ALL (US$), June'2022
Figure 8-600: Blincyto - Sales Value by Region (US$ Million), Q1'2022
Figure 8-601: Blincyto - Sales Value by Region (%), Q1'2022
Figure 8-602: Blincyto - Sales Value (US$ Million), 2018 - 2021
Figure 8-603: US - Blincyto Sales Value (US$ Million), 2018 - 2021
Figure 8-604: ROW - Blincyto Sales Value (US$ Million), 2018 - 2021
Figure 8-605: Global - Blincyto Quarterly Sales Value (US$ Millions), 2021
Figure 8-606: US - Blincyto Quarterly Sales Value (US$ Millions), 2021
Figure 8-607: ROW - Blincyto Quarterly Sales Value (US$ Millions), 2021
Figure 8-608: Blincyto - Sales Value by Region (US$ Million), 2021
Figure 8-609: Blincyto - Sales Value by Region (%), 2021
Figure 8-610: Global - Blincyto Sales Forecast (US$ Million), 2022 - 2028
Figure 8-611: US - Blincyto Sales Forecast (US$ Million), 2022 - 2028
Figure 8-612: Tafasitamab - FDA Orphan Designation Year by Region
Figure 8-613: US - Monjuvi Orphan Drug Designation Approval & Exclusivity Year
Figure 8-614: Tafasitamab - Approval Year by Region
Figure 8-615: Monjuvi - Number of Dose per Treatment Cycle by Phase
Figure 8-616: Monjuvi - Duration of Single Treatment Cycle & Full Treatment (Weeks)
Figure 8-617: Monjuvi - Cost of Single Dose, Single Treatment Cycle & Full Treatment (US$), June'2022
Figure 8-618: Global - Monjuvi Sales Value (US$ Million), Q'2021 & Q1'2022
Figure 8-619: Global - Monjuvi Sales Value (US$ Million), 2020 & 2021
Figure 8-620: Global - Monjuvi Quarterly Sales Value (US$ Million), 2021
Figure 8-621: US - Monjuvi Sales Value (US$ Million), Q3 & Q4'2020
Figure 8-622: Global - Monjuvi Sales Forecast (US$ Million), 2022 - 2028
Figure 8-623: US - Bosulif Orphan Drug Designation & Approval Year
Figure 8-624: Bosulif - Approval Year by Region
Figure 8-625: US - Bosulif Approval by Indication
Figure 8-626: US - Bosulif Patent Approval & Expiration Year
Figure 8-627: Europe - Bosutif EMA Approval & Patent Exclusivity Year
Figure 8-628: Bosulif - Cost of Supply of 120 Tablets & Per Unit Cost of 100mg (US$), June'2022
Figure 8-629: Bosulif - Cost of Supply of 120 Tablets & Per Unit Cost of 400mg & 500mg (US$), June'2022
Figure 8-630: Bosutinib - Initial Recommended Dose by Indication for Adults (mg/day)
Figure 8-631: Bosutinib - Minimum & Maximum Recommended Dose (mg/day)
Figure 8-632: Bosulif - Sales by Region (US$ Million), Q1'2022
Figure 8-633: Bosulif - Sales Value by Region (%), Q1'2022
Figure 8-634: Global - Bosulif Sales Value (US$ Million), 2017-2021
Figure 8-635: US - Bosulif Sales Value (US$ Million), 2017-2021
Figure 8-636: Europe - Bosulif Sales Value (US$ Million), 2017-2021
Figure 8-637: Bosulif - Sales by Region (US$ Million), 2021
Figure 8-638: Bosulif - Sales Value by Region (%), 2021
Figure 8-639: Bosulif - Sales Value by Region (%), 2020
Figure 8-640: Global - Bolusif Quarterly Sales (US$ Million), 2021
Figure 8-641: US - Bolusif Quarterly Sales (US$ Million), 2021
Figure 8-642: Europe - Bolusif Quarterly Sales (US$ Million), 2021
Figure 8-643: Global - Bosulif Quarterly Sales (US$ Million), 2020
Figure 8-644: US - Bosulif Quarterly Sales (US$ Million), 2020
Figure 8-645: Global - Bolusif Sales Forecast (US$ Million), 2022 - 2028
Figure 8-646: US - Bolusif Sales Forecast (US$ Million), 2022 - 2028
Figure 8-647: Europe - Bolusif Sales Forecast (US$ Million), 2022 - 2028
Figure 8-648: ROW - Bolusif Sales Forecast (US$ Million), 2022 - 2028
Figure 8-649: US - Xalkori Orphan Drug Designation by Indication
Figure 8-650: US - Xalkori Orphan Patent Exclusivity Year by Indication
Figure 8-651: US - Xalkori Approval Year by Indication
Figure 8-652: Xalkori - Approval Year by Region
Figure 8-653: US - Xalkori Patent Approval & Expiration Year
Figure 8-654: Xalkori - Cost of Supply of 60 Capsules & Per Unit Cost of Oral Capsule (US$), June'2022
Figure 8-655: Xalkori - Recommended Initial & Subsequent Dose Reductions (mg/day)
Figure 8-656: Xalkori - Sales by Region (US$ Million), Q1'2022
Figure 8-657: Xalkori - Sales Value by Region (%), Q1'2022
Figure 8-658: Global - Xalkori Sales Value (US$ Million), 2019-2021
Figure 8-659: US - Xalkori Sales Value (US$ Million), 2019-2021
Figure 8-660: Europe - Xalkori Sales Value (US$ Million), 2019-2021
Figure 8-661: Xalkori - Sales by Region (US$ Million), 2021
Figure 8-662: Xalkori - Sales Value by Region (%), 2021
Figure 8-663: Global - Xalkori Quarterly Sales (US$ Million), 2021
Figure 8-664: US - Xalkori Quarterly Sales (US$ Million), 2021
Figure 8-665: Europe - Xalkori Quarterly Sales (US$ Million), 2021
Figure 8-666: Global - Xalkori Quarterly Sales (US$ Million), 2020
Figure 8-667: US - Xalkori Quarterly Sales (US$ Million), 2020
Figure 8-668: Global - Xalkori Sales Forecast (US$ Million), 2022 - 2028
Figure 8-669: US - Empliciti Orphan Designation & FDA Approval Year
Figure 8-670: Empliciti - FDA Approval by Therapy Type
Figure 8-671: Empliciti - Approval Year by Region
Figure 8-672: Empliciti - Patent Issue & Expiration Year
Figure 8-673: US - Price for 300mg & 400mg Supply of Empliciti Intravenous Powder for Injection (US$), June'2022
Figure 8-674: Empliciti - Number of Dose Administration During Initial 2 Cycles & Subsequent Cycles
Figure 8-675: Empliciti - Cost of Single Cycle during Initial 2 Cycles & Subsequent Cycles (US$), June'2022
Figure 8-676: Global - Empliciti Sales Value by Region (US$ Million), Q1'2022
Figure 8-677: Global - Empliciti Sales Value by Region (%), Q1'2022
Figure 8-678: Global - Empliciti Sales Value (US$ Million), 2018 - 2020
Figure 8-679: US - Empliciti Sales Value (US$ Million), 2018 - 2020
Figure 8-680: Global - Empliciti Sales Value by Region (US$ Million), 2021
Figure 8-681: Global - Empliciti Sales Value by Region (%), 2021
Figure 8-682: Global - Empliciti Quarterly Sales Value (US$ Million), 2021
Figure 8-683: US - Empliciti Quarterly Sales Value (US$ Million), 2021
Figure 8-684: Global - Empliciti Quarterly Sales Value (US$ Million), 2020
Figure 8-685: US - Empliciti Quarterly Sales Value (US$ Million), 2020
Figure 8-686: Global - Empliciti Sales Forecast (US$ Million), 2022 - 2028
Figure 8-687: US - Empliciti Sales Forecast (US$ Million), 2022 - 2028
Figure 8-688: US - Lorbrena Orphan Drug Designation Approval & Exclusivity Year
Figure 8-689: Lorbrena - Approval Year by Region
Figure 8-690: US - Lorbrena Patent Approval & Expiration Year
Figure 8-691: Lorbrena - Cost of Supply of 30 Tablets & Per Unit Cost of 25mg Oral Tablet (US$), June'2022
Figure 8-692: Lorbrena - Cost of Supply of 30 Tablets & Per Unit Cost of 100mg Oral Tablet (US$), June'2022
Figure 8-693: Lorbrena - Recommended Initial & Subsequent Dose Reductions (mg/day)
Figure 8-694: Lorbrenna - Sales by Region (US$ Million), Q1'2022
Figure 8-695: Lorbrenna - Sales Value by Region (%), Q1'2022
Figure 8-696: Global - Lorbrenna Sales Value (US$ Million), 2019-2021
Figure 8-697: US - Lorbrenna Sales Value (US$ Million), 2019-2021
Figure 8-698: Europe - Lorbrenna Sales Value (US$ Million), 2019-2021
Figure 8-699: Lorbrenna - Sales by Region (US$ Million), 2021
Figure 8-700: Lorbrenna - Sales Value by Region (%), 2021
Figure 8-701: Global - Lorbrenna Quarterly Sales (US$ Million), 2021
Figure 8-702: US - Lorbrenna Quarterly Sales (US$ Million), 2021
Figure 8-703: Europe - Lorbrenna Quarterly Sales (US$ Million), 2021
Figure 8-704: Global - Lorbrenna Quarterly Sales (US$ Million), 2020
Figure 8-705: US - Lorbrenna Quarterly Sales (US$ Million), 2020
Figure 8-706: Global - Lorbrena Sales Forecast (US$ Million), 2022 - 2028
Figure 8-707: US - Lorbrena Sales Forecast (US$ Million), 2022 - 2028
Figure 8-708: Europe - Lorbrena Sales Forecast (US$ Million), 2022 - 2028
Figure 8-709: US - Lurbinectedin Orphan Drug Designation Approval & Exclusivity Year
Figure 8-710: Lurbinectedin - Orphan Designation Year by Region
Figure 8-711: US - Lurbinectedin Orphan Designation & FDA Approval Year
Figure 8-712: Zepzelca - Patent Issue & Expiration Year
Figure 8-713: Zepzelca - Recommended Initial & Subsequent Dose Reductions (mg/m2)
Figure 8-714: Global - Zepzelca Sales Value (US$ Million), Q1'2021 & Q1'2022
Figure 8-715: Global - Zepzelca Sales Value (US$ Million), 2020 & 2021
Figure 8-716: Global - Zepzelca Quarterly Sales (US$ Million), 2021
Figure 8-717: Global - Zepzelca Quarterly Sales (US$ Million), Q3 & Q4'2020
Figure 8-718: Global - Zepzelca Sales Forecast (US$ Million), 2022 - 2028
Figure 8-719: US - Mektovi Orphan Drug Designation Approval & Exclusivity Year
Figure 8-720: US - Mektovi Orphan Designation & FDA Approval Year
Figure 8-721: Mektovi - Cost of Supply of 180 Tablets & Per Unit Cost of Oral Tablet (US$), June'2022
Figure 8-722: Mektovi - Recommended Initial & Subsequent Dose Reduction (mg)
Figure 8-723: Global - Mektovi Sales Value (US$ Million), Q1'2021 & Q1'2022
Figure 8-724: Global - Mektovi Sales Value (US$ Million), 2019-2021
Figure 8-725: Global - Mektovi Quarterly Sales (US$ Million), 2021
Figure 8-726: Global - Mektovi Quarterly Sales (US$ Million), 2020
Figure 8-727: Global - Mektovi Sales Forecast (US$ Million), 2022 - 2028
Figure 8-728: US - Lenvatinib Orphan Drug Designation Approval by Indication
Figure 8-729: US - Lenvatinib Orphan Drug Designation Approval & Exclusivity Year
Figure 8-730: US - Lenvima Approval Year by Indication
Figure 8-731: US - Lenvima Patent Approval & Expiration Year
Figure 8-732: Lenvima - Cost of Supply of 60 Capsules & Per Unit Cost of 14mg, 8mg, & 20mg Oral Tablet (US$), June'2022
Figure 8-733: Lenvima - Cost of Supply of 90 Capsules & Per Unit Cost of 12mg, 18mg, & 24mg Oral Tablet (US$), June'2022
Figure 8-734: Lenvima - Cost of Supply of 30 Capsules & Per Unit Cost of 4mg, & 10mg Oral Tablet (US$), June'2022
Figure 8-735: Lenvima - Recommended Initial Dose by Indication (mg)
Figure 8-736: Global - Lenvima Sales Value (US$ Million), Q1'2021 & Q1'2022
Figure 8-737: Global - Lenvima Sales Value (US$ Million), 2018 - 2021
Figure 8-738: Global - Lenvima Quarterly Sales Value (US$ Million), 2021
Figure 8-739: Global - Lenvima Quarterly Sales Value (US$ Million), 2020
Figure 8-740: Global - Lenvima Sales Forecast (US$ Million), 2022 - 2028
Figure 8-741: US - Zanubrutinib Orphan Drug Designation Approval by Indication
Figure 8-742: US - Zanubrutinib FDA Approval by Indication
Figure 8-743: Brukinsa - Approval Year by Region
Figure 8-744: US - Brukinsa Patent Approval & Expiration Year
Figure 8-745: Brukinsa - Cost of Supply of 120 Capsules & Per Unit Cost of 80mg Oral Capsule (US$), June'2022
Figure 8-746: Global - Brukinsa Sales Value (US$ Million), Q1'2021 & Q1'2022
Figure 8-747: Global - Brukinsa Sales Value (US$ Million), 2020 & 2021
Figure 8-748: Global - Brukinsa Quarterly Sales Value (US$ Million), 2021
Figure 8-749: Global - Brukinsa Quarterly Sales Value (US$ Million), 2020
Figure 8-750: Global - Brukinsa Sales Forecast (US$ Million), 2022 - 2028
Figure 8-751: US - Regorafenib Orphan Drug Designation Approval by Indication
Figure 8-752: US - Stivarga Approval Year by Indication
Figure 8-753: Stivarga - Approval Year by Region
Figure 8-754: US - Stivarga Patent Approval & Expiration Year
Figure 8-755: Stivarga - Cost of Supply of 84 Tablets & Per Unit Cost of 40mg Oral Tablet (US$), June'2022
Figure 8-756: Stivarga - Recommended Initial & Subsequent Dose Reduction (mg)
Figure 8-757: Global - Stivarga Sales Value (Euro/US$ Million), Q1'2021 & Q1'2022
Figure 8-758: Global - Stivarga Sales Value (Euro/US$ Million), 2018 - 2021
Figure 8-759: Global - Stivarga Quarterly Sales Value (Euro/US$ Million), 2021
Figure 8-760: Global - Stivarga Quarterly Sales Value (Euro/US$ Million), 2020
Figure 8-761: Global - Stivarga Sales Forecast (US$ Million), 2022 - 2028
Figure 8-762: US - Cabozantinib Orphan Drug Designation Approval by Indication
Figure 8-763: Cabozantinib - Orphan Drug Designation Approval by Region
Figure 8-764: US - Cabozantinib FDA Approval by Brand Name
Figure 8-765: Europe - Cabozantinib FDA Approval by Brand Name
Figure 8-766: US - Cabometyx FDA Approval by Indication
Figure 8-767: US - Cabozantinib Patent Approval & Expiration Year
Figure 8-768: Cometriq - Cost of Supply of 56 Capsules & Per Unit Cost of 100mg Oral Capsule (US$), June'2022
Figure 8-769: Cometriq - Cost of Supply of 112 Capsules & Per Unit Cost of 140mg Oral Capsule (US$), June'2022
Figure 8-770: Cometriq - Cost of Supply of 84 Capsules & Per Unit Cost of 60mg Oral Capsule (US$), June'2022
Figure 8-771: Cabometyx - Cost of Supply of 30 Tablets & Per Unit Cost of Oral Tablet (US$), June'2022
Figure 8-772: Cabozantinib - Recommended Dosage by Indication (mg/day)
Figure 8-773: Global - Cabozantinib Sales Value (US$ Million), Q1'2021 & Q1'2022
Figure 8-774: Global - Cabozantinib Sales Value (US$ Million), 2020 & 2021
Figure 8-775: Global - Cabozantinib Quarterly Sales Value (US$ Million), 2021
Figure 8-776: Global - Cabozantinib Sales Forecast (US$ Million), 2022 - 2028
Figure 8-777: US - Iressa Orphan Designation & FDA Approval Year
Figure 8-778: Iressa - Cost of Supply of 30 Tablets & Per Unit Cost of Oral Tablet (US$), June'2022
Figure 8-779: Iressa - Sales Value by Region (US$ Million), Q1'2022
Figure 8-780: Iressa - Sales Value by Region (US$ Million), Q1'2022
Figure 8-781: Global - Iressa Sales Value (US$ Million), 2019 - 2021
Figure 8-782: Global - Iressa Quarterly Sales Value (US$ Million), 2021
Figure 8-783: US - Kymriah Orphan Designation by Indication
Figure 8-784: Europe - Kymriah Orphan Designation by Indication
Figure 8-785: US - Kymriah FDA Approval by Indication
Figure 8-786: Europe - Kymriah EMA Approval by Indication
Figure 8-787: Kymriah - Approval & Patent Exclusivity Year by Region
Figure 8-788: Global - Kymriah Sales Value (US$ Million), Q1'2021 & Q1'2022
Figure 8-789: Global - Kymriah Sales Value (US$ Million), 2019 - 2021
Figure 8-790: Global - Kymriah Quarterly Sales (US$ Million), 2021
Figure 8-791: Global - Kymriah Quarterly Sales (US$ Million), 2020
Figure 8-792: Global - Kymriah Sales Forecast Value (US$ Million), 2022 - 2028
Figure 8-793: US - Yescarta Orphan Designation by Indication
Figure 8-794: Europe - Yescarta Orphan Designation by Indication
Figure 8-795: US - Yescarta FDA Approval by Indication
Figure 8-796: Yescarta - Approval Year by Region
Figure 8-797: US - Yescarta FDA Approval & Patent Expiration Year
Figure 8-798: Yescarta - Global Sales by Region (US$ Million), Q1'2022
Figure 8-799: Yescarta - Global Sales by Region (%), Q1'2022
Figure 8-800: Global - Yescarta Sales Value (US$ Million), 2018 - 2021
Figure 8-801: US - Yescarta Sales Value (US$ Million), 2018 - 2021
Figure 8-802: Yescarta - Global Sales Value by Region (US$ Million), 2021
Figure 8-803: Yescarta - Global Sales Value by Region (%), 2021
Figure 8-804: Global - Yescarta Quarterly Sales (US$ Million), 2021
Figure 8-805: US - Yescarta Quarterly Sales (US$ Million), 2021
Figure 8-806: Europe - Yescarta Quarterly Sales (US$ Million), 2021
Figure 8-807: Global - Yescarta Quarterly Sales (US$ Million), 2020
Figure 8-808: Global - Yescarta Sales Forecast (US$ Million), 2022 - 2028
Figure 8-809: US - Yescarta Sales Forecast (US$ Million), 2022 - 2028
Figure 8-810: Europe - Yescarta Sales Forecast (US$ Million), 2022 - 2028
Figure 8-811: Tecartus - Orphan Designation by Region
Figure 8-812: US - Tecartus FDA Approval by Indication
Figure 8-813: Tecartus - Global Sales by Region (US$ Million), Q1'2022
Figure 8-814: Tecartus - Global Sale by Region (%), Q1'2022
Figure 8-815: Global - Tecartus Sales Value (US$ Million), 2020 & 2021
Figure 8-816: US - Tecartus Sales Value (US$ Million), 2020 & 2021
Figure 8-817: Tecartus - Global Sales Value by Region (US$ Million), 2021
Figure 8-818: Tecartus - Global Sales Value by Region (%), 2021
Figure 8-819: Global - Yescarta Quarterly Sales (US$ Million), 2021
Figure 8-820: US - Yescarta Quarterly Sales (US$ Million), 2021
Figure 8-821: Europe - Yescarta Quarterly Sales (US$ Million), 2021
Figure 8-822: Global - Tecartus Sales Forecast (US$ Million), 2022 - 2028
Figure 8-823: US - Tecartus Sales Forecast (US$ Million), 2022 - 2028
Figure 8-824: US - Breyanzi Orphan Designation by Indication
Figure 8-825: Breyanzi - Approval Year by Region
Figure 8-826: Breyanzi - Global Sales by Region (US$ Million), Q1'2022
Figure 8-827: Breyanzi - Global Sales by Region (%), Q1'2022
Figure 8-828: Global - Breyanzi Quarterly Sales (US$ Million), Q2-Q4'2021
Figure 8-829: Global - Breyanzi Sales Forecast (US$ Million), 2022 - 2028
Figure 8-830: US - Breyanzi Sales Forecast (US$ Million), 2022 - 2028
Figure 8-831: Abecma - Orphan Designation by Region
Figure 8-832: Abecma - Approval Year by Region
Figure 8-833: Abecma - Global Sales by Region (US$ Million), Q1'2022
Figure 8-834: Abecma - Global Sales by Region (%), Q1'2022
Figure 8-835: Abecma - Global Sales by Region (US$ Million), 2021
Figure 8-836: Abecma - Global Sales by Region (%), 2021
Figure 8-837: Global - Abecma Quarterly Sales (US$ Million), Q2-Q4'2021
Figure 8-838: US - Abecma Quarterly Sales (US$ Million), Q2-Q4'2021
Figure 8-839: Global - Abecma Sales Forecast (US$ Million), 2022 - 2028
Figure 8-840: US - Abecma Sales Forecast (US$ Million), 2022 - 2028
Figure 9-1: Global - Orphan Cancer Drugs Clinical Pipeline by Company (Number), 2022 till 2028
Figure 9-2: Global - Orphan Cancer Drugs Clinical Pipeline by Drug Class (Number), 2022 till 2028
Figure 9-3: Global - Orphan Cancer Drugs Clinical Pipeline by Indication (Number), 2022 till 2028
Figure 9-4: Global - Orphan Cancer Drugs Clinical Pipeline by Priority Status (Number), 2022 till 2028
Figure 9-5: Global - Orphan Cancer Drugs Clinical Pipeline by Phase (Number), 2022 till 2028